1350456-56-2

Basic information

• Product Name: FMoc-Val-Cit-PAB-MMAE
• Synonyms: FMoc-Val-Cit-PAB-MMAE
• CAS NO: 1350456-56-2
• Molecular Formula: C73H104N10O14
• Molecular Weight: 1345.66546
• Mol File: 1350456-56-2.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: FMoc-Val-Cit-PAB-MMAE(CAS DataBase Reference)
• NIST Chemistry Reference: FMoc-Val-Cit-PAB-MMAE(1350456-56-2)
• EPA Substance Registry System: FMoc-Val-Cit-PAB-MMAE(1350456-56-2)

Safety Data

• Hazardous Substances Data: 1350456-56-2(Hazardous Substances Data)

Usage

Description

Fmoc-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate containing a cleavable Val-Cit peptide, a PABC linker and a MMAE payload. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells.

Uses

Fmoc-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate containing a cleavable Val-Cit peptide, a PABC linker and a MMAE payload. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells.

Upstream product

• 863971-53-3 (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((S)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate 
• 1057314-02-9 N-phenyl maleimide monomethyl-auristatin-E 
• 474645-27-7 [3H]-Vedotin 

Relevant articles and documents

PHOSPHOLIPID ETHER CONJUGATES AS CANCER-TARGETING DRUG VEHICLES

Disclosed herein are therapeutic compounds capable of targeting a broad range of tumor cells. The present disclosure is further directed to compositions comprising the therapeutic compounds, methods of manufacturing the therapeutic compounds, and methods of treating cancer comprising administering the therapeutic compounds.

SELF-STABILIZING LINKER CONJUGATES

The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.

PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE

The present disclosure relates to a process for preparing an intermediate of antibody-drug conjugate. Compared with the conventional art, the process for preparing an intermediate of the antibody-drug conjugate provided by the present disclosure significantly reduces the feed loss for drug moiety, such as MMAD/MMAE or MMAF, etc., as drug moiety is involved in the last step of the reaction, thereby effectively reducing production costs, as well as increasing production efficiency. In addition, the process provided by the present disclosure is simple, environmentally friendly and suitable for large-scale industrialization.